CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-384

That’s all good, we have a great forum here with many intelligent posters who provide great value, so I am happy to contribute where I can. I agree with most here, except one immature child of course. Based on the current fundamentals, this should really be trading between 50 cents and $1 at least, but I would continue to hold even if it went above those prices with the current fundamentals. We have clear proof of sustained sales momentum, and it is continuing to accelerate. This includes, surprisingly to me, revenue generated outside the US as well. There is also the recent announcements that have substantially improved the outlook, such as the reimbursement news. The market will need to price this all in sooner than later, the numbers drive the share price and the market will never let a stock remain so significantly undervalued if the existing fundamentals warrant a substantially higher valuation. It does take time sometimes, but in all my time investing I have found the re-rate always eventually happens for those companies that continue to deliver strong results, as has been the case for this company.